Palisade Bio, Inc. (PALI)

7.74 +0.45 (+6.17%) At close: 04:00PM EDT

Palisade Bio, Inc.

7750 El Camino Real
Suite 2A
Carlsbad, CA 92009
United States
858 704 4900
https://www.palisadebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Mr. J. D. Finley	CEO, CFO & Director	791.33k	N/A	1958
Dr. Mitchell Lawrence Jones M.D., Ph.D.	COO & Chief Medical Officer	635k	N/A	1978
Mr. Ryker Willie	Senior VP of Finance & Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Corporate governance

Palisade Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.